LONDON--(BUSINESS WIRE)--Tenpoint Therapeutics (“Tenpoint”), a biotechnology company pursuing vision-restoring engineered cell-based therapeutics and in vivo reprogramming to address degenerative ...
Tenpoint Therapeutics said it has secured $235 million in new capital, combining an $85 million Series B preferred stock financing with a $150 million senior secured term loan facility, as the company ...
A restaurant menu, a book, a smartphone and other everyday objects have come alive in Tenpoint Therapeutics’ first consumer campaign for the presbyopia-treating eye drop, Yuvezzi. Complete with fuzzy ...
Oppenheimer & Co.’s 2025 Biotech in the Berkshires is being held on August 4–6 in the Berkshires, MA. Tenpoint Therapeutics' President and Chief Business Officer Ben Bergo and Melissa Epperly, Chief ...
LONDON & WARREN, N.J., July 13, 2026--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global commercial ophthalmic pharmaceutical company focused on developing groundbreaking treatments to improve ...
LONDON & SEATTLE, January 29, 2026--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd., a global, commercial biotechnology company focused on developing groundbreaking treatments to improve vision in the ...
In a phase 3 trial, Tenpoint Therapeutics’ eye drop—a combination of carbachol and brimonidine—improved vision for patients with presbyopia for up to eight hours. The top-line results come from ...
For some degenerative vision disorders, the therapies available don’t restore sight, they mainly slow its decline. To realize this benefit, a patient must receive an eye injection as frequently as ...
Tenpoint Therapeutics Launches YUVEZZI™ Direct-to-Consumer Campaign Featuring a Cast of Hand-Crafted Puppets Giving a Voice to the Everyday Fusses of Blurry Close-Up Vision The campaign, called ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results